Akebia Therapeutics Dividend
Dividend criteria checks 0/6
Akebia Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
n/a
Payout ratio
| Industry average yield | 2.9% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Earnings per share | -US$0.25 |
| Dividend yield forecast in 3Y | n/a |
Recent dividend updates
No updates
Recent updates
Akebia's Vafseo Faces Grim Market Outlook (Rating Downgrade)
Apr 02There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 30% Share Price Rise
Mar 19
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Share Price Boosted 31% But Its Business Prospects Need A Lift Too
Jan 05Positive Sentiment Still Eludes Akebia Therapeutics, Inc. (NASDAQ:AKBA) Following 27% Share Price Slump
Jun 23Is Akebia Therapeutics (NASDAQ:AKBA) Using Debt Sensibly?
Mar 02Akebia Therapeutics: FDA Approval Failure, Terminated Partnerships, And Looming LOE - Too Risky
Oct 07Broker Revenue Forecasts For Akebia Therapeutics, Inc. (NASDAQ:AKBA) Are Surging Higher
Aug 10Akebia regains rights to kidney disease therapy after termination of deals with Otsuka
Jun 30Another Look At Akebia Therapeutics
Sep 06Is Akebia Therapeutics (NASDAQ:AKBA) Using Debt In A Risky Way?
Jun 24Akebia wins $40M Department of Veterans Affairs contract
Jun 15FDA accepts Akebia's vadadustat NDA for review
Jun 01Should Shareholders Reconsider Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) CEO Compensation Package?
May 26Akebia EPS misses by $0.08, beats on revenue
May 10Akebia highlights late-stage vadadustat kidney disease study results
Apr 28Akebia Therapeutics, Inc. (NASDAQ:AKBA): When Will It Breakeven?
Mar 31Have Insiders Been Selling Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares This Year?
Mar 10Have Insiders Sold Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares Recently?
Mar 10Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if AKBA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AKBA's dividend payments have been increasing.
Dividend Yield vs Market
| Akebia Therapeutics Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (AKBA) | n/a |
| Market Bottom 25% (US) | 1.6% |
| Market Top 25% (US) | 4.8% |
| Industry Average (Biotechs) | 2.9% |
| Analyst forecast in 3 Years (AKBA) | n/a |
Notable Dividend: Unable to evaluate AKBA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AKBA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate AKBA's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as AKBA has not reported any payouts.